mivocabtagene autoleucel (miv-cel)
Jump to navigation
Jump to search
Indications
- investigational treatment of stiff person syndrome
Dosage
- lymphodepletion with low-dose cyclophosphamide& fludarabine followed by a single infusion of mivocabtagene autoleucel at a target dose of 1108 CAR T cells
Mechanism of action
- autologous CD19 CAR-T cell therapy eliminates B cells
More general terms
References
- ↑ George J Stiff Person Syndrome Patients Regain Mobility After Single-Dose Cell Therapy. CAR-T therapy shows promise in clinical trial. MedPage Today. April 23, 2026 https://www.medpagetoday.com/meetingcoverage/aan/120926